Ritonavir Helps Control HIV for 48 Weeks in Children

Sunday, August 4th, 2013

A recent study suggests that children undergoing darunavir-ritonavir treatment can maintain viral control for 48 weeks along with an optimized background treatment regimen. The study, which is called ARIEL, 81 percent of the children aged between three and five years could achieve viral suppression to negligible amounts. This is an increase in suppression rate at […]

Simplified HIV Treatment Regimens with Ritonavir Could Increase Adverse Effect Risk

Friday, August 2nd, 2013

Two separate studies looked at how a simpler treatment regimen with lesser pill burden could affect patients diagnosed with the viral infection. Both studies returned mixed results. The simplified treatment regimens proved to be as effective as more pill-intensive treatments, but there was a significant increase in adverse side effects. The first study focused on […]

Price of Ritonavir and Other AIDS Treatment Medicines Down

Tuesday, July 2nd, 2013

A report by the Medecins Sans Frontieres released at the International AIDS Society conference, Kuala Lumpur, has shed light on the pricing trends of important AIDS treatment medications. It shows that prices of key medicines in second-line treatment- ritonavir, atazanavir, and lopinavir- have fallen by an average of 28 percent each. The most affordable second-line […]

Positive Outlook of Patients towards HIV Clinical Studies

Tuesday, June 11th, 2013

A recent survey of participants of the Gender, Race, and Clinical Experience (GRACE) trial shows that a majority of the participants would recommend taking part in a clinical trial to others. The GRACE trial was the largest study involving female adult HIV patients who experienced treatment. The trial aimed to examine differences in HIV therapy […]